Similar Search Results

Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

Taylor, Douglas; Pandya, Ankur; Thompson, David; Chu, Paula - In: The European Journal of Health Economics 10 (2009) 3, pp. 255-265

Persistent link: https://www.econbiz.de/10005004366

Decision-analytical modelling in health-care economic evaluations

Sun, Xin; Faunce, Thomas - In: The European Journal of Health Economics 9 (2008) 4, pp. 313-323

Persistent link: https://www.econbiz.de/10005167131

What reimbursement for coronary revascularization with drug-eluting stents?

Tarricone, Rosanna; Marchetti, Monia; Lamotte, Mark; … - In: The European Journal of Health Economics 5 (2004) 4, pp. 309-316

Persistent link: https://www.econbiz.de/10009404312

Transforming EQ-5D utilities for use in cost–value analysis of health programs

Nord, Erik; Johansen, Rune - In: The European Journal of Health Economics 16 (2015) 3, pp. 313-328

compression and decreasing marginal value of utility gains. We review evidence on the strength of concerns for the worse off … utility improvements with different start levels. Concerns for severity show up quite strongly across countries, sample types … of decreasing marginal value of utility gains. Using the central tendency in the data we present two plausible …

Persistent link: https://www.econbiz.de/10011240886

SF-6D Portuguese population norms

Ferreira, Pedro; Ferreira, Lara; Pereira, Luis - In: The European Journal of Health Economics 16 (2015) 3, pp. 235-241

This study reports Portuguese population norms measured using the SF-6D based on a national representative sample. These results can be used as reference data to inform policy. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2015

Persistent link: https://www.econbiz.de/10011240888

Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain

Hidalgo-Vega, Álvaro; Ramos-Goñi, Juan; Villoro, Renata - In: The European Journal of Health Economics 15 (2014) 9, pp. 917-925

Ranolazine is a highly efficient add-on therapy for the symptomatic treatment of chronic angina pectoris in patients who are inadequately controlled by, or intolerant to, first-line antianginal therapies in Spain. </AbstractSection> Copyright Springer-Verlag Berlin Heidelberg 2014

Persistent link: https://www.econbiz.de/10011151208

Priorities and Prospect Theory

Happich, M.; Mazurek, B. - In: The European Journal of Health Economics 3 (2002) 1, pp. 40-46

Whose preferences are to be used for cost-effectiveness analysis? It has been recommended that community preferences for health states are the most appropriate ones for use in a reference case analysis. However, critics maintain that persons are not able properly to judge a health state if they...

Persistent link: https://www.econbiz.de/10010993816

Modelling the costs and effects of leflunomide in rheumatoid arthritis

Kobelt, G.; Lindgren, P.; Young, A. - In: The European Journal of Health Economics 3 (2002) 3, pp. 180-187

This study investigated the cost-effectiveness of leflunomide (LEF) compared to methotrexate (MTX) and sulfasalazine (SSZ) in the United Kingdom. A Markov model was constructed using health states defined by Health Assessment Questionnaire score. The model is based on a cohort of patients with...

Persistent link: https://www.econbiz.de/10010993821

Health state utilities for skeletal-related events secondary to bone metastases

Matza, Louis; Chung, Karen; Brunt, Kate; Brazier, John; … - In: The European Journal of Health Economics 15 (2014) 1, pp. 7-18

All SREs were associated with statistically significant utility decreases, suggesting a perceived impact on quality of … life beyond the impact of cancer with bone metastases. The resulting disutilities may be used in cost-utility models …

Persistent link: https://www.econbiz.de/10010993892

Valuing EQ-5D using Time Trade-Off in France

Chevalier, Julie; Pouvourville, Gérard - In: The European Journal of Health Economics 14 (2013) 1, pp. 57-66

This study provides the French value set of the EQ-5D based on the stated preferences of the French general public facilitating cost-effectiveness analysis. </AbstractSection> Copyright Springer-Verlag 2013

Persistent link: https://www.econbiz.de/10010993930